{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:44:12Z","timestamp":1765233852046,"version":"3.40.5"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>The impact of SARS-CoV-2 infection among people living with HIV (PLWH) has been a matter of research. We evaluated the incidence and factors associated with SARS-CoV-2 diagnosis among PLWH. We also assessed factors related to vaccination coverage in the Balearic Islands.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A retrospective analytical study was performed, including patients from the Balearic cohort (EVHIA) who were visited at least twice between 1<jats:sup>st<\/jats:sup> January 2020 and 31<jats:sup>st<\/jats:sup> March 2022. Chi-square test and Mann-Whitney U test were used to compare categorical and continuous variables respectively. Multivariable Cox proportional hazards regression models were estimated to identify risk factors.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 3567 patients with HIV were included. The median age was 51 years (IQR 44\u201359). Most of them were male (77,3%), from Europe (82,1%) or South America (13,8%). During the study period 1036 patients were diagnosed with SARS-CoV-2 infection (29%). The incidence rate was 153,24 cases per 1000 person-year. After multivariable analysis, men who have sex with men (MSM) were associated with an increased risk of SARS-CoV-2 infection (adjusted hazard ratio 1,324, 95% CI 1,138\u20131,540), whereas African origin, tobacco use and complete or booster vaccination coverage were negatively related. Overall, complete vaccination or booster coverage was recorded in 2845 (79,75%) patients. When analysing vaccination uptake, older patients (adjusted hazard ratio 5,122, 95% CI 3,170\u20138,288) and those with a modified comorbidity index of 2\u20133 points (adjusted hazard ratio 1,492, 95% CI 1,056\u20132,107) had received more vaccine doses.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In our study no HIV related factor was associated with an increased risk of SARS-CoV-2 infection, except for differences in the transmission route. Possible confounding variables such as mask wearing or social interactions could not be measured. Vaccines were of utmost importance to prevent SARS-CoV-2 infection. Efforts should be made to encourage vaccination in those groups of PLWH with less coverage.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0308568","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T17:39:01Z","timestamp":1723052341000},"page":"e0308568","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factors associated with SARS-CoV-2 infection among people living with HIV: Data from the Balearic cohort (EVHIA)"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1952-8273","authenticated-orcid":true,"given":"Francisca","family":"Artigues Serra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Pinecki Socias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Fanjul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Pe\u00f1aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Homar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Sorni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adelaida","family":"Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lola","family":"Ventayol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Dolores","family":"Macia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria \u00c0ngels","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melchor","family":"Riera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"pone.0308568.ref001","article-title":"RENAVE. CNE. CNM (ISCIII). Primeros casos investigados en Espa\u00f1a por COVID-2019","author":"Equipo COVID-19","year":"2020","journal-title":"Informe no 1"},{"key":"pone.0308568.ref002","unstructured":"Equipo COVID-19. RENAVE. CNE. CNM (ISCIII). Informe no 161. Situaci\u00f3n de COVID-19 en Espa\u00f1a. Diciembre, 2022."},{"key":"pone.0308568.ref003","unstructured":"Govern de les Illes Balears. CORONAVIRUS A LA COMUNITAT AUT\u00d2NOMA DE LES ILLES BALEARS-Visor COVID-19 Illes Balears [Internet]. Balearic Islands Covid-19 Visor. Periodic update. [cited 2022 Dec 26]. Available from: https:\/\/www.caib.es\/sites\/covid-19\/ca\/visor_covid-19_illes_balears\/"},{"key":"pone.0308568.ref004","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s11904-021-00579-6","article-title":"HIV and SARS \u2011 CoV \u2011 2 Co \u2011 infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most \u2011 at \u2011 Risk Groups","author":"DK Nomah","year":"2021","journal-title":"Curr HIV\/AIDS Rep"},{"key":"pone.0308568.ref005","first-page":"1","article-title":"Socioeconomic differences in COVID \u2011 19 infection, hospitalisation and mortality in urban areas in a region in the South of Europe","volume":"6","author":"NF Fern\u00e1ndez-Mart\u00ednez","year":"2022","journal-title":"BMC Public Health"},{"issue":"4","key":"pone.0308568.ref006","first-page":"67","article-title":"Population Risk Factors for Severe Disease and Mortality in COVID-19 in the United States during the Pre-Vaccine Era: A Retrospective Cohort Study of National Inpatient Sample","volume":"10","author":"K Raj","year":"2022","journal-title":"Med Sci"},{"issue":"166","key":"pone.0308568.ref007","doi-asserted-by":"crossref","first-page":"220098","DOI":"10.1183\/16000617.0098-2022","article-title":"Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta- analysis of cohort studies in Europe","volume":"31","author":"CI Vardavas","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"11","key":"pone.0308568.ref008","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/cid\/cir627","article-title":"Premature age-related comorbidities among HIV-infected persons compared with the general population","volume":"53","author":"G Guaraldi","year":"2011","journal-title":"Clin Infect Dis"},{"key":"pone.0308568.ref009","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1016\/S2352-3018(21)00070-9","article-title":"Overview of SARS-CoV-2 infection in adults living with HIV","volume":"8","author":"J Ambrosioni","year":"2021","journal-title":"Lancet HIV"},{"issue":"11","key":"pone.0308568.ref010","doi-asserted-by":"crossref","first-page":"e701","DOI":"10.1016\/S2352-3018(21)00240-X","article-title":"Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study","volume":"8","author":"DK Nomah","year":"2021","journal-title":"Lancet HIV"},{"issue":"7","key":"pone.0308568.ref011","doi-asserted-by":"crossref","first-page":"e1964","DOI":"10.1093\/cid\/ciaa1339","article-title":"Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019","volume":"73","author":"D Dandachi","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pone.0308568.ref012","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jcph.1788","article-title":"Antiretrovirals for Prophylaxis Against COVID-19: A Comprehensive Literature Review","volume":"61","author":"G Alavian","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"pone.0308568.ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/life12122089","article-title":"HIV and SARS-CoV-2 Co-Infection: From Population Study Evidence to In Vitro Studies","volume":"12","author":"C Stefani","year":"2022","journal-title":"Life"},{"key":"pone.0308568.ref014","unstructured":"Grupo de Trabajo Vacunaci\u00f3n. Estrategia de vacunaci\u00f3n frente a COVID\u201419 en Espa\u00f1a. 2 de diciembre 2020. 2020."},{"key":"pone.0308568.ref015","unstructured":"Grupo de Trabajo Vacunaci\u00f3n. Estrategia de vacunaci\u00f3n frente a COVID\u201419 en Espa\u00f1a. Actualizaci\u00f3n 9 modificada. 2 de noviembre 2021. 2021."},{"key":"pone.0308568.ref016","unstructured":"Ministerio de Sanidad. Informe de actividad diario. GIV\u2013Gesti\u00f3n Integral de vacunaci\u00f3n frente al COVID-19 en Espa\u00f1a. Enero, 2023."},{"issue":"5","key":"pone.0308568.ref017","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/QAI.0000000000002896","article-title":"Incidence and Severity of SARS-CoV-2 Infection in HIV-Infected Individuals during the First Year of the Pandemic","volume":"89","author":"D Rial-Crestelo","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0308568.ref018","first-page":"1","author":"M Fernandez-fuertes","year":"2021","journal-title":"Incidence of and factors associated with SARS-CoV-2 infection among people living with HIV in Southern Spain after one year of pandemic"},{"key":"pone.0308568.ref019","first-page":"1","article-title":"Risk of SARS-CoV-2 Infection Among People Living With HIV in Wuhan, China","volume":"10","author":"M Wu","year":"2022","journal-title":"Front Public Heal"},{"issue":"15","key":"pone.0308568.ref020","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1097\/QAD.0000000000003075","article-title":"SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV","volume":"35","author":"MA Spinelli","year":"2021","journal-title":"AIDS"},{"key":"pone.0308568.ref021","article-title":"Population-based assessment of SARS-CoV-2 infection among people living with HIV and the general population of Catalonia","author":"DK Nomah","year":"2023","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"pone.0308568.ref022","first-page":"1","article-title":"SARS-CoV-2 Vaccination Coverage and Factors Associated with Low Uptake in a Cohort of People Living with HIV","author":"DK Nomah","year":"2022","journal-title":"Cdc"},{"issue":"1","key":"pone.0308568.ref023","first-page":"1","article-title":"COVID-19 vaccination in people living with HIV and AIDS (PLWHA) in China: A cross-sectional study","volume":"19","author":"X Lv","year":"2023","journal-title":"Hum Vaccines Immunother"},{"issue":"1","key":"pone.0308568.ref024","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1089\/apc.2021.0144","article-title":"SARS-CoV-2 Vaccination Hesitancy and Behaviors in a National Sample of People Living with HIV","volume":"36","author":"J Jaiswal","year":"2022","journal-title":"AIDS Patient Care STDS"},{"issue":"9","key":"pone.0308568.ref025","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3390\/vaccines10091569","article-title":"Immunogenicity and Safety of COVID-19 Vaccines among People Living with HIV: A Systematic Review and Meta-Analysis","volume":"10","author":"L Kang","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"pone.0308568.ref026","first-page":"1","article-title":"A Systematic Review of COVID-19 Vaccine Antibody Responses in People With HIV","volume":"9","author":"HM Chun","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"January","key":"pone.0308568.ref027","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijid.2022.11.035","article-title":"Effectiveness of COVID-19 vaccines in people living with HIV in British Columbia and comparisons with a matched HIV-negative cohort: a test-negative design","volume":"127","author":"A Fowokan","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"1","key":"pone.0308568.ref028","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0000000000003429","article-title":"COVID-19 vaccine immunogenicity in people with HIV","volume":"37","author":"CT Costiniuk","year":"2023","journal-title":"Aids"},{"key":"pone.0308568.ref029","article-title":"Booster shot of inactivated SARS \u2010 CoV \u2010 2 vaccine induces potent immune responses in people living with HIV","author":"H Zhan","year":"2023","journal-title":"J Med Virol"},{"key":"pone.0308568.ref030","article-title":"COVID-19 in people with HIV in the Netherlands, the ATHENA cohort study","author":"FW Wit","year":"2023","journal-title":"Aids"},{"key":"pone.0308568.ref031","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijid.2022.05.055","article-title":"Risk Factors Associated with Severe\/Critical COVID-19 in People Living with HIV-1","volume":"122","author":"A Bachelard","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"5","key":"pone.0308568.ref032","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1089\/aid.2021.0159","article-title":"SARS-COV-2 Infection in People Living with HIV: Experience from a Tertiary Hospital in Madrid","volume":"38","author":"M Gonz\u00e1lez Guembre","year":"2022","journal-title":"AIDS reserch Hum retroviruses"},{"issue":"7","key":"pone.0308568.ref033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamanetworkopen.2023.23349","article-title":"Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials","volume":"6","author":"DA Theodore","year":"2023","journal-title":"JAMA Netw Open"},{"key":"pone.0308568.ref034","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cmi.2021.06.023","article-title":"Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort","volume":"27","author":"J Berenguer","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"pone.0308568.ref035","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/QAD.0000000000003223","article-title":"Racial and ethnic disparities in coronavirus disease 2019 disease incidence independent of comorbidities, among people with HIV in the United States","volume":"36","author":"RA Bender","year":"2022","journal-title":"AIDS"},{"issue":"6","key":"pone.0308568.ref036","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/bmjebm-2020-111492","article-title":"Is there a smoker\u2019s paradox in COVID-19?","volume":"26","author":"MS Usman","year":"2021","journal-title":"BMJ Evidence-Based Med"},{"key":"pone.0308568.ref037","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study","volume":"253","author":"AA Elfiky","year":"2020","journal-title":"Life Sci"},{"issue":"5","key":"pone.0308568.ref038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph14050454","article-title":"Tenofovir, another inexpensive, well-known and widely available old drug repurposed for sars-cov-2 infection","volume":"14","author":"I Zanella","year":"2021","journal-title":"Pharmaceuticals"},{"key":"pone.0308568.ref039","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1097\/QAD.0000000000003372","article-title":"Tenofovir disoproxil fumarate \/ emtricitabine and severity of coronavirus disease 2019 in people with HIV infection","volume":"36","author":"J Del Amo","year":"2022","journal-title":"AIDS"},{"key":"pone.0308568.ref040","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/QAD.0000000000003314","article-title":"Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV","volume":"36","author":"G Li","year":"2022","journal-title":"AIDS"},{"issue":"10","key":"pone.0308568.ref041","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/cid\/ciad084","article-title":"Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis from 6 United States Cohorts before Vaccine Rollout","volume":"76","author":"AN Lea","year":"2023","journal-title":"Clin Infect Dis"},{"key":"pone.0308568.ref042","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/jac\/dkac177","article-title":"Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study","volume":"77","author":"DK Nomah","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"pone.0308568.ref043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v15051127","article-title":"Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV","volume":"15","author":"MF Rombini","year":"2023","journal-title":"Viruses"},{"issue":"3","key":"pone.0308568.ref044","doi-asserted-by":"crossref","first-page":"E116","DOI":"10.1093\/cid\/ciac628","article-title":"Tenofovir Disoproxil Fumarate\/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial","volume":"76","author":"R Montejano","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0308568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T17:40:06Z","timestamp":1723052406000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0308568"}},"subtitle":[],"editor":[{"given":"Jake M.","family":"Pry","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0308568","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,8,7]]}}}